OS Therapies Incorporated: Business Overview, Financials & Competitive Analysis
OS Therapies Incorporated scores 5/10 on the AskCyborg Cyborg Score (Mixed). Transformative clinical data in high-unmet-need indication offset by near-term liquidity and execution risks requiring successful regulatory navigation and capital markets timing. OS Therapies reported compelling Phase IIb clinical data showing 75% two-year overall survival for OST-HER2 in recurrent pulmonary metastatic osteosarcoma versus 40% historical control, demonstrating strong clinical progress.
What is OS Therapies Incorporated's industry? OS Therapies Incorporated (ostherapies.com) operates in Clinical-Stage Biopharmaceutical - Oncology Immunotherapy & Antibody Drug Conjugates. AskCyborg classifies OS Therapies Incorporated under Clinical-Stage Biopharmaceutical - Oncology Immunotherapy & Antibody Drug Conjugates in its company registry.
OS Therapies is the world leader in listeria-based cancer immunotherapies, focusing on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. Its lead asset OST-H...
Cyborg Score thesis
Transformative clinical data in high-unmet-need indication offset by near-term liquidity and execution risks requiring successful...
Read the full analyst-debate transcript →Get the Latest OS Therapies Incorporated Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeOS Therapies Incorporated Overview
Pro stress-test →OS Therapies is the world leader in listeria-based cancer immunotherapies, focusing on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. Its lead asset OST-HER2 met its Phase 2b osteosarcoma trial primary endpoint achieving a 35% 12-month event-free survival rate versus roughly 20% in historical controls, with interim two-year assessments showing 75% of patients still alive versus about 40% in historical controls.
Strategic Profile
Pro stress-test →The company intends to submit a Biologics License Application for OST-HER2 in osteosarcoma by end of January 2026 aiming for FDA Accelerated Approval in Q3 2026, and conditional Marketing Authorisation Applications to the UK's MHRA (end of January 2026) and the EMA (end of February 2026). OS Therapies' wholly owned subsidiary OS Animal Health filed a Form S-1 to pursue an IPO in 1H 2026, with shareholders expected to receive 1 OSAH share per 10 OSTX shares, focusing on commercializing OST-HER2 for canine osteosarcoma and other HER2-positive animal cancers.
Competitive Landscape
Pro stress-test →OS Therapies operates in a fragmented landscape where primary rivals include fellow clinical-stage specialist Cellectar Biosciences with its phospholipid drug conjugate iopofosine I 131, which has shown exploratory activity but lacks the immune memory mechanism of OST-HER2; OSTX's Phase IIb data is more mature and statistically robust, giving it a potential first-mover advantage. Large pharma giants GSK, Merck, and AstraZeneca have ADC or immuno-oncology programs that could apply to osteosarcoma, but their focus is diluted across massive portfolios.
Industry Context
OS Therapies Incorporated operates in Clinical-Stage Biopharmaceutical - Oncology Immunotherapy & Antibody Drug Conjugates.
Key facts
Founded: 2018 · Headquarters: Grasonville, Maryland, US · Revenue: $0 · Market cap: $58.8M